182 related articles for article (PubMed ID: 32993745)
41. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
42. How far should we go in optimal cytoreductive surgery for ovarian cancer?
Hernandez-Lopez LA; Elizalde-Mendez A
Chin Clin Oncol; 2020 Oct; 9(5):70. PubMed ID: 32954737
[TBL] [Abstract][Full Text] [Related]
43. Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data.
Abdallah R; Chon HS; Bou Zgheib N; Marchion DC; Wenham RM; Lancaster JM; Gonzalez-Bosquet J
Int J Gynecol Cancer; 2015 Jul; 25(6):1000-9. PubMed ID: 26098088
[TBL] [Abstract][Full Text] [Related]
44. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
Nica A; Covens A; Parra-Herran C; May T
Gynecol Oncol; 2020 Sep; 158(3):622-630. PubMed ID: 32561124
[TBL] [Abstract][Full Text] [Related]
45. Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas.
Gurkan D; Ceren Akin A; Sahin H; Aytac Tohma Y; Sahin EA; Gunakan E; Iflazoglu N; Nihan Haberal A; Ayhan A
J Obstet Gynaecol; 2020 May; 40(4):551-557. PubMed ID: 31482736
[TBL] [Abstract][Full Text] [Related]
46. Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: prospective validation. "The times they are a-changin"?
Ceccaroni M; Roviglione G; Bruni F; Clarizia R; Ruffo G; Salgarello M; Peiretti M; Uccella S
Surg Endosc; 2018 Apr; 32(4):2026-2037. PubMed ID: 29052073
[TBL] [Abstract][Full Text] [Related]
47. An update on preoperative assessment of the resectability of advanced ovarian cancer.
Kadhel P; Revaux A; Carbonnel M; Naoura I; Asmar J; Ayoubi JM
Horm Mol Biol Clin Investig; 2019 Aug; 41(3):. PubMed ID: 31398144
[TBL] [Abstract][Full Text] [Related]
48. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer.
Cham S; Chen L; St Clair CM; Hou JY; Tergas AI; Melamed A; Ananth CV; Neugut AI; Hershman DL; Wright JD
Am J Obstet Gynecol; 2019 Jun; 220(6):571.e1-571.e8. PubMed ID: 30771346
[TBL] [Abstract][Full Text] [Related]
49. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
[TBL] [Abstract][Full Text] [Related]
50. Development of a Novel Intra-Operative Score to Record Diseases' Anatomic Fingerprints (ANAFI Score) for the Prediction of Complete Cytoreduction in Advanced-Stage Ovarian Cancer by Using Machine Learning and Explainable Artificial Intelligence.
Laios A; Kalampokis E; Johnson R; Munot S; Thangavelu A; Hutson R; Broadhead T; Theophilou G; Nugent D; De Jong D
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765924
[TBL] [Abstract][Full Text] [Related]
51. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.
van de Laar R; Massuger LF; Van Gorp T; IntHout J; Zusterzeel PL; Kruitwagen RF
Gynecol Oncol; 2015 May; 137(2):210-5. PubMed ID: 25677063
[TBL] [Abstract][Full Text] [Related]
52. Learning curve of high-complexity surgery for advanced ovarian cancer.
Nishikimi K; Tate S; Matsuoka A; Shozu M
Gynecol Oncol; 2020 Jan; 156(1):54-61. PubMed ID: 31735352
[TBL] [Abstract][Full Text] [Related]
53. Machine Learning-Based Risk Prediction of Critical Care Unit Admission for Advanced Stage High Grade Serous Ovarian Cancer Patients Undergoing Cytoreductive Surgery: The Leeds-Natal Score.
Laios A; De Oliveira Silva RV; Dantas De Freitas DL; Tan YS; Saalmink G; Zubayraeva A; Johnson R; Kaufmann A; Otify M; Hutson R; Thangavelu A; Broadhead T; Nugent D; Theophilou G; Gomes de Lima KM; De Jong D
J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011828
[TBL] [Abstract][Full Text] [Related]
54. Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers.
Kawakami E; Tabata J; Yanaihara N; Ishikawa T; Koseki K; Iida Y; Saito M; Komazaki H; Shapiro JS; Goto C; Akiyama Y; Saito R; Saito M; Takano H; Yamada K; Okamoto A
Clin Cancer Res; 2019 May; 25(10):3006-3015. PubMed ID: 30979733
[TBL] [Abstract][Full Text] [Related]
55. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index.
Llueca A; Serra A; Rivadulla I; Gomez L; Escrig J;
World J Surg Oncol; 2018 Feb; 16(1):37. PubMed ID: 29471831
[TBL] [Abstract][Full Text] [Related]
56. Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.
Kumar A; Sheedy S; Kim B; Suidan R; Sarasohn DM; Nikolovski I; Lakhman Y; McGree ME; Weaver AL; Chi D; Cliby WA
Gynecol Oncol; 2019 Jul; 154(1):72-76. PubMed ID: 31000471
[TBL] [Abstract][Full Text] [Related]
57. Surgical Complexity Impact on Survival After Complete Cytoreductive Surgery for Advanced Ovarian Cancer.
Martinez A; Ngo C; Leblanc E; Gouy S; Luyckx M; Darai E; Classe JM; Guyon F; Pomel C; Ferron G; Filleron T; Querleu D
Ann Surg Oncol; 2016 Aug; 23(8):2515-21. PubMed ID: 27008588
[TBL] [Abstract][Full Text] [Related]
58. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
[TBL] [Abstract][Full Text] [Related]
59. Novel Surgical Strategies in the Treatment of Gynecological Malignancies.
Angeles MA; Martínez-Gómez C; Migliorelli F; Voglimacci M; Figurelli J; Motton S; Tanguy Le Gac Y; Ferron G; Martinez A
Curr Treat Options Oncol; 2018 Nov; 19(12):73. PubMed ID: 30411170
[TBL] [Abstract][Full Text] [Related]
60. Transitory Stoma at the Time of Complete Cytoreductive Surgery Affects Survival for Patients with Advanced-stage Ovarian Cancer.
Canlorbe G; Touboul C; Chargari C; Bentivegna E; Maulard A; Pautier P; Genestie C; Morice P; Gouy S
Anticancer Res; 2018 Mar; 38(3):1517-1523. PubMed ID: 29491080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
